Abstracts tagged "registry"

Abstract Number: 1543 • 2019 ACR/ARP Annual Meeting
Long-Term Effectiveness and Safety of Infliximab, Golimumab and Ustekinumab in Psoriatic Arthritis Patients from a Prospective Observational Registry
Proton Rahman ¹, Regan Arendse ², Isabelle Fortin ³, Andrew Chow ⁴, Majed Khraishi ⁵, Suneil Kapur ⁶, Michel Zummer ⁷, Raheem Kherani ⁸, Jonathan Chan ⁹, Emmanouil Rampakakis ¹⁰, Meagan Rachich ¹¹, Odalis Asin-Milan ¹¹, Allen Lehman ¹¹ and Francois Nantel¹¹, ¹Memorial University, Newfoundland, NL, Canada, ²University of Saskatchewan, Saskatoon, SK, Canada, ³Centre de Rhumatologie de l'Est du Quebec, Rimouski, QC, Canada, ⁴Credit Valley Rheumatology, Mississauga, ON, Canada, ⁵Nexus Clinical Research, Memorial University of Newfoundland, St. Johns, NL, Canada, ⁶University of Ottawa, Ottawa, ON, Canada, ⁷Ch Maisonneuve-Rosemont, Montreal, QC, Canada, ⁸University of British Columbia, Richmond, BC, Canada, ⁹Artus Health Clinic, Vancouver, BC, Canada, ¹⁰JSS Medical Research, Montreal, Canada, ¹¹Janssen Inc., Toronto, ON, Canada
Background/Purpose: Long-term registries are essential to evaluate new therapies in a patient population that differs from clinical trials and usually varies over time. The purpose of…
Abstract Number: 1544 • 2019 ACR/ARP Annual Meeting
Predictors of Response, Adverse Events and Treatment Retention in Ankylosing Spondylitis Patients Treated with Golimumab in a Prospective, Observational Registry
Proton Rahman ¹, Ariel Masetto ², Michelle Teo ³, Pauline Boulos ⁴, Dalton Sholter ⁵, Suneil Kapur ⁶, Emmanouil Rampakakis ⁷, Meagan Rachich ⁸, Odalis Asin-Milan ⁸, Allen Lehman ⁸ and Francois Nantel⁸, ¹Memorial University, Newfoundland, NL, Canada, ²Université de Sherbrooke, Sherbrooke, QC, Canada, ³Balfour Medical Clinic, Penticton, BC, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵Rheumatology Associates, Edmonton, AB, Canada, ⁶University of Ottawa, Ottawa, ON, Canada, ⁷JSS Medical Research, Montreal, Canada, ⁸Janssen Inc., Toronto, ON, Canada
Background/Purpose: The Biologic Treatment Registry Across Canada (BioTRAC) was a prospective, observational registry that enrolled ankylosing spondylitis (AS) (radiographic axial SpA) patients treated with subcutaneous…
Abstract Number: 2286 • 2019 ACR/ARP Annual Meeting
Mobile Responsive App – Useful Additional Tool for Data Collection in the German Pregnancy Register Rhekiss?
Jutta Richter¹, Christina Bungartz ², Anja Weiß ³, Rebecca Fischer-Betz ⁴, Angela Zink ⁵, Matthias Schneider ¹ and Anja Strangfeld ³, ¹Department and Hiller Research Unit of Rheumatology, Heinrich-Heine University Duesseldorf, Duesseldorf, Nordrhein-Westfalen, Germany, ²German Rheumatism Research Center (DRFZ), Berlin, Berlin, Germany, ³German Rheumatism Research Center (DRFZ), Berlin, Germany, ⁴Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany, ⁵German Rheumatism Research Centre and Charité University medicine, Berlin, Germany
Background/Purpose: The German pregnancy register Rhekiss is designed as a nationwide, web-based longitudinal observational register established in 2015. The register follows women with inflammatory rheumatic…
Abstract Number: 2373 • 2019 ACR/ARP Annual Meeting
Two Decades of Changes in RA Treatment and Disease Outcomes from the United States
Sofia Pedro¹, Alyssa Dominique ², Rebecca Schumacher ¹, Yomei Shaw ¹, Kristin Wipfler ¹, Teresa Simon ³ and Kaleb Michaud ⁴, ¹FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ²Bristol-Myers Squibb, Princeton, NJ, ³Bristol-Myers Squibb*, Princeton, NJ, ⁴FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS
Background/Purpose: RA causes significant morbidity and mortality. Over the last two decades, several new medications and strategies for treating RA earlier and more aggressively have…
Abstract Number: 2477 • 2019 ACR/ARP Annual Meeting
Burden of Disease at Treatment Initiation Among Biologic-Naïve Patients with Oligoarticular versus Polyarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Alexis Ogdie¹, Mei Liu ², Meghan Glynn ³, Kelechi Emeanuru ², Leslie Harrold ⁴, Sven Richter ⁵, Benoit Guerette ⁵ and Philip Mease ⁶, ¹Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ²Corrona, LLC, Waltham, MA, ³Corrona, LLC, Waltham, ⁴Corrona, LLC and University of Massachusetts Medical School, Worcester, MA, ⁵Celgene Corporation, Summit, ⁶Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA
Background/Purpose: Oligoarticular PsA accounts for ≈50% of PsA worldwide, but only a paucity of data describes disease burden among these patients. The Corrona PsA/SpA Registry,…
Abstract Number: 2722 • 2019 ACR/ARP Annual Meeting
The down Syndrome Arthropathy Cohort in the New Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: Clinical Characteristics, Treatment and Outcomes
Jordan Jones¹, Daniel J. Lovell ², Chelsey Smith ³ and Mara Becker ⁴, ¹Children's Mercy Kansas City, Kansas City, MO, ²Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, ³Children's Mercy Kansas City, Kansas, MO, ⁴Duke Children's Hospital, Durham, NC
Background/Purpose: Down syndrome arthropathy (DA) is under-recognized with a 19-month average delay in diagnosis (1). The majority present with polyarticular, rheumatoid factor (RF) and anti-nuclear…
Abstract Number: 2850 • 2019 ACR/ARP Annual Meeting
Exploring Heterogeneity in Rheumatoid Arthritis: Outcomes up to 4 Years of Follow-Up in Patient Clusters Identified by Data-driven Analysis of the BRASS Registry
Jeffrey Curtis¹, Michael Weinblatt ², Kenneth Saag ¹, Vivian Bykerk ³, Christina Charles-Schoeman ⁴, Stefano Fiore ⁵, Gregory St John ⁶, Toshio Kimura ⁷, Shen Zheng ⁵, Clifton Bingham ⁸, Grace Wright ⁹, Martin Bergman ¹⁰, Kamala Nola ¹¹, Daniel Furst ⁴ and Nancy Shadick ², ¹University of Alabama at Birmingham, Birmingham, AL, ²Brigham and Women's Hospital, Boston, MA, ³Hospital for Special Surgery, New York City, NY, ⁴University of California, Los Angeles, CA, ⁵Sanofi Genzyme, Bridgewater, NJ, ⁶Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁷Regeneron Pharmaceuticals, Inc, Tarrytown, NY, ⁸Johns Hopkins University, Baltimore, MD, ⁹Private Practice, New York City, NY, ¹⁰Drexel University College of Medicine, Stockholm, Sweden, ¹¹Lipscomb University College of Pharmacy & Health Sciences, Nashville, TN
Background/Purpose: Patients with rheumatoid arthritis (RA) may share characteristics that relate to their future outcomes. We investigated clinical outcomes over a 4-year follow-up period in…
Abstract Number: 2908 • 2019 ACR/ARP Annual Meeting
Remission in Patients with Rheumatoid Arthritis Receiving Triple Therapy Compared to Biological Therapy – A Swedish Nationwide Register Study
Hanna Källmark¹, Jon Einarsson ², Jan-Åke Nilsson ³ and Meliha Kapetanovic ², ¹Lund University, Lund, Sweden, ²Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Section of Rheumatology, Lund and Malmö, Sweden, Lund, Sweden, ³Skane University Hospital, Lund and Malmö, Sweden, Lund, Sweden
Background/Purpose: Current treatment guidelines for rheumatoid arthritis (RA) recommend a treat-to-target approach with early treatment initiation of disease-modifying antirheumatic drugs (DMARDs), most commonly methotrexate (MTX),…
Abstract Number: 183 • 2019 ACR/ARP Annual Meeting
Exploring Heterogeneity in Rheumatoid Arthritis: Patient Profiling Through Principal Component and Cluster Analysis of the BRASS Registry
Jeffrey Curtis¹, Michael Weinblatt ², Kenneth Saag ¹, Vivian Bykerk ³, Christina Charles-Schoeman ⁴, Stefano Fiore ⁵, Gregory St John ⁶, Toshio Kimura ⁷, Shen Zheng ⁵, Clifton Bingham ⁸, Grace Wright ⁹, Martin Bergman ¹⁰, Kamala Nola ¹¹, Daniel Furst ⁴ and Nancy Shadick ², ¹University of Alabama at Birmingham, Birmingham, AL, ²Brigham and Women's Hospital, Boston, MA, ³Hospital for Special Surgery, New York City, NY, ⁴University of California, Los Angeles, CA, ⁵Sanofi Genzyme, Bridgewater, NJ, ⁶Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁷Regeneron Pharmaceuticals, Inc, Tarrytown, NY, ⁸Johns Hopkins University, Baltimore, MD, ⁹Private Practice, New York City, NY, ¹⁰Drexel University College of Medicine, Stockholm, Sweden, ¹¹Lipscomb University College of Pharmacy & Health Sciences, Nashville, TN
Background/Purpose: Data-driven principal component (PC) and cluster analysis has the potential to identify previously unknown patient subgroups within a rheumatoid arthritis (RA) registry to establish…
Abstract Number: 432 • 2019 ACR/ARP Annual Meeting
Does Improvement in Patient Pain and Fatigue Lag Behind Clinical Remission in Rheumatoid Arthritis Patients? Data from a Rheumatoid Arthritis Registry
Janet Pope¹, Emmanouil Rampakakis ², Mohammad Movahedi ³, Angela Cesta ⁴, John Sampalis ² and Claire Bombardier ⁴, ¹Western University, London, ON, Canada, ²JSS Medical Research, Montreal, Canada, ³Ontario Best Practices Research Initiative, Toronto General Research Institute University Health Network, Toronto, Canada, ⁴Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Rheumatoid arthritis (RA) patients are often not in remission due to patient global assessment of disease activity (PtGA) which is included in the formula…
Abstract Number: 215 • 2018 ACR/ARHP Annual Meeting
A Decade Earlier- Onset of Symptoms of RA in the Indian (Asian) Cohort Compared to Dutch Cohort: Based on Meteor, a Global Database
Arvind Chopra¹, Manjit Saluja², Sytske Anne Bergstra³, Toktam Kainifard⁴, Anuradha Venugopalan⁵ and Tom W.J. Huizinga³, ¹Center for Rheumatic Diseases, Pune, India, ²Rheumatology, Research Co-ordinator, Pune, India, ³Department of Rheumatology, LUMC, Leiden, Netherlands, ⁴Rheumatology, Consultant research and Dietitian, Tehran, Iran (Islamic Republic of), ⁵Rheumatology, R & D, Lab, Center for Rheumatic Diseases, Pune, India
Background/Purpose: Reported symptom onset and diagnosis debut in rheumatoid arthritis (RA) patients may be influenced by environmental factors, genetics and gene-environmental interactions, but also by…
Abstract Number: 274 • 2018 ACR/ARHP Annual Meeting
Socioeconomic Disparities in Disease Activity in Patients with Rheumatoid Arthritis
Lei Zhu¹, Evelyn Talbott² and Larry W. Moreland¹, ¹Division of Rheumatology and Clinical Immunology, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Epidemiology, University of Pittsbugh, Pittsburgh, PA
Background/Purpose: To develop a methodology for well-defined rheumatoid arthritis (RA) measurement as an outcome and provide a clear definition of social determinants related to disease…
Abstract Number: 549 • 2018 ACR/ARHP Annual Meeting
Unmet Treat-to-Target Goals with Available Targeted Immunomodulators in the Management of Rheumatoid Arthritis: Real World Evidence from the Corrona Registry
Dimitrios A. Pappas^1,2, Namita Tundia³, Ying Shan², Heather J Litman² and Joel Kremer⁴, ¹Columbia University, New York, NY, ²Corrona, LLC, Southborough, MA, ³AbbVie Inc., North Chicago, IL, ⁴Albany Medical College and the Center for Rheumatology, Albany, NY
Background/Purpose: Targeted immunomodulators (TIMs) have revolutionized the therapy of RA and made low disease activity (LDA) a realistic goal for patients. Given the multiple therapy…
Abstract Number: 580 • 2018 ACR/ARHP Annual Meeting
Clinical Effectiveness of Tofacitinib 11mg Once Daily (QD) Versus Tofacitinib 5mg Twice Daily (BID) in the Corrona US RA Registry
Stanley Cohen¹, Heather J Litman², Connie Chen³, Tatjana Lukic³, Ann Madsen³, Liza Takiya⁴, Kimberly J Dandreo², Taylor Blachley² and Jeffrey Greenberg², ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Corrona LLC, Waltham, MA, ³Pfizer Inc, New York, NY, ⁴Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA, originally approved at 5 mg twice daily (BID). In 2016, an extended-release…
Abstract Number: 606 • 2018 ACR/ARHP Annual Meeting
Similiar Efficacy of Tofacinitib on Disease Activity in Rheumatoid Arthritis Patients with and without Previous Biologicals; Results from the Turkbio Regıstry
Berrin Zengin¹, Nevsun Inanc², Servet Akar³, Gerçek Can¹, Ediz Dalkiliç⁴, Abdurrahman Tufan⁵, Soner Senel⁶, Suleyman Serdar Koca⁷, Handan Yarkan¹, Yavuz Pehlivan⁸, Zeynep Erturk⁹, Berna Goker⁵, Haner Direskeneli², Merih Birlik¹, Nurullah Akkoc¹⁰ and Fatos Onen¹, ¹Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ²Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ³Faculty of Medicine, Department of Rheumatology, Izmir Katip Celebi University, Izmir, Turkey, ⁴Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey, ⁵Internal Medicine-Rheumatology, Gazi University Faculty of Medicine, Ankara, Turkey, ⁶Rheumatology, Kayseri Erciyes University, Faculty of Medicine, Kayseri, Turkey, ⁷Rheumatology, Firat University Faculty of Medicine, Elazığ, Turkey, ⁸Rheumatology, Uludag University, Faculty of Medicine, Bursa, Turkey, ⁹Rheumatology, Marmara University Faculty of Medicine, istanbul, Turkey, ¹⁰Rheumatology, İzmir, Turkey, İzmir, Turkey
Background/Purpose: Tofacitinib, a JAK3 inhibitor has been used to treat patients with rheumatoid arthritis (RA) in Turkey since 2015. The aim of this study was…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].